Research Advances of POSTN in Cardiovascular Diseases

doi:10.19586/j.2095-2341.2023.0085

Current Biotechnology ›› 2023, Vol. 13 ›› Issue (5): 725-729.DOI: 10.19586/j.2095-2341.2023.0085

• Reviews • Previous Articles Next Articles

Research Advances of POSTN in Cardiovascular Diseases

Xuesheng FANG¹^,²^,³(), Mingwei BAO¹^,²^,³()

^1.Department of Cardiology，Renmin Hospital of Wuhan University，Wuhan 430060，China
^2.Cardiovascular Research Institute of Wuhan University，Wuhan 430060，China
^3.Hubei Key Laboratory of Cardiology，Wuhan 430060，China

Received:2023-06-15 Accepted:2023-07-10 Online:2023-09-25 Published:2023-10-10
Contact: Mingwei BAO

骨膜蛋白在心血管疾病中的研究进展

方学升¹^,²^,³(), 包明威¹^,²^,³()

^1.武汉大学人民医院心血管内科，武汉 430060
^2.武汉大学心血管病研究所，武汉 430060
^3.湖北省心血管病重点实验室，武汉 430060

通讯作者: 包明威
作者简介:方学升E-mail: 912689491@qq.com；
基金资助:
国家自然科学基金项目(81970438)

Abstract

Abstract:

Cardiovascular disease is the leading cause of death from chronic diseases worldwide， and disease prevention and treatment have brought a heavy burden to the country. Periostin （POSTN） is an extracellular matrix related protein that involved in various biological processes such as cell proliferation， migration， differentiation and inflammatory response. Recent studies have shown that POSTN is widely implicated in the occurrence and development of cardiovascular diseases， such as atherosclerosis， vascular calcification， cardiac remodeling after myocardial infarction， pulmonary hypertension， valvular heart disease， etc. This article reviewed the research advances of POSTN in cardiovascular diseases， and provided new ideas for early detection， early diagnosis， early treatment and prognostic evaluation of cardiovascular diseases with POSTN as the target.

Key words: POSTN, atherosclerosis, myocardial infarction, pulmonary hypertension, valvular heart disease

摘要：

心血管疾病是导致全球慢性疾病死亡的首要原因，其防治给国家带来了沉重的负担。骨膜蛋白（periostin，POSTN）是一种细胞外基质相关蛋白，参与细胞增殖、迁移、分化和炎症反应等多种生物学过程。近年来研究发现POSTN参与动脉粥样硬化、血管钙化、心肌梗死后心脏重塑、肺动脉高压、心脏瓣膜等心血管疾病的发生发展。综述了POSTN在心血管疾病中的研究进展，以期为心血管疾病的早期发现、早期诊断、早期治疗及预后评估提供新思路。

关键词: 骨膜蛋白, 动脉粥样硬化, 心肌梗死, 肺动脉高压, 瓣膜性心脏病

CLC Number:

Q816

Xuesheng FANG, Mingwei BAO. Research Advances of POSTN in Cardiovascular Diseases[J]. Current Biotechnology, 2023, 13(5): 725-729.

方学升, 包明威. 骨膜蛋白在心血管疾病中的研究进展[J]. 生物技术进展, 2023, 13(5): 725-729.

References 37

1	中国心血管健康与疾病报告编写组.中国心血管健康与疾病报告2021概要[J].中国循环杂志,2022,37(6):553-578.
2	LANDRY N M, COHEN S, DIXON I M C. Periostin in cardiovascular disease and development: a tale of two distinct roles[J/OL]. Basic. Res. Cardiol., 2018, 113(1): 1[2023-06-02]. .
3	KII I. Practical application of periostin as a biomarker for pathological conditions[J]. Adv. Exp. Med. Biol., 2019, 1132: 195-204.
4	YANG L, GUO T, CHEN Y, et al.. The multiple roles of periostin in non-neoplastic disease[J/OL]. Cells, 2022, 12(1): 50[2023-06-09]. .
5	BJÖRKEGREN J L M, LUSIS A J. Atherosclerosis: recent developments[J]. Cell, 2022, 185(10): 1630-1645.
6	CAO L, ZHANG Z, LI Y, et al.. LncRNA H19/miR-let-7 axis participates in the regulation of ox-LDL-induced endothelial cell injury via targeting periostin[J]. Int. Immunopharmacol., 2019, 72: 496-503.
7	SINGH S, TORZEWSKI M. Fibroblasts and their pathological functions in the fibrosis of aortic valve sclerosis and atherosclerosis[J/OL]. Biomolecules, 2019, 9(9): 472[2023-06-03]. .
8	WANG Z, LI G, LI M, et al.. Periostin contributes to the adventitial remodeling of atherosclerosis by activating adventitial fibroblasts[J]. Atheroscler Plus., 2022, 50: 57-64.
9	GAO F, BAI R, QIN W, et al.. Angiotensin Ⅱ induces the expression of periostin to promote foam cell formation in oxLDL-treated macrophages[J]. Int. J. Cardiol., 2022, 347: 46-53.
10	PAN W, JIE W, HUANG H. Vascular calcification: molecular mechanisms and therapeutic interventions[J/OL]. MedComm., 2023, 4(1): e200[2023-03-08]. .
11	ALESUTAN I, HENZE L A, BOEHME B, et al.. Periostin augments vascular smooth muscle cell calcification via β-catenin signaling[J/OL]. Biomolecules, 2022, 12(8): 1157[2023-03-09]. .
12	SUN X, MA W, ZHU Y, et al.. Postn promotes diabetic vascular calcification by interfering with autophagic flux[J/OL]. Cell Signal., 2021, 83: 109983[2022-03-05]. .
13	ZHU Y, JI J, WANG X, et al.. Periostin promotes arterial calcification through PPARγ-related glucose metabolism reprogramming[J]. Am. J. Physiol. Heart Circ. Physiol., 2021, 320(6): 2222-2239.
14	SÖZMEN M, DEVRIM A K, KABAK Y B, et al.. The effects of periostin in a rat model of isoproterenol: mediated cardiotoxicity[J]. Cardiovasc. Toxicol., 2018, 18(2): 142-160.
15	KIM B R, JANG I H, SHIN S H, et al.. Therapeutic angiogenesis in a murine model of limb ischemia by recombinant periostin and its fasciclin I domain[J]. Biochim. Biophys. Acta, 2014, 1842(9): 1324-1332.
16	THENAPPAN T, ORMISTON M L, RYAN J J, et al.. Pulmonary arterial hypertension: pathogenesis and clinical management[J/OL]. Brit. Med. J., 2018, 360: j5492[2022-03-18]. .
17	MARTIN DE MIGUEL I, CRUZ-UTRILLA A, OLIVER E, et al.. Novel molecular mechanisms involved in the medical treatment of pulmonary arterial hypertension[J/OL]. Int. J. Mol. Sci., 2023, 24(4): 4147[2023-03-24]. .
18	YOSHIDA T, NAGAOKA T, NAGATA Y, et al.. Periostin‐related progression of different types of experimental pulmonary hypertension: a role for M2 macrophage and FGF‐2 signalling[J]. Respirology, 2022, 27(7): 529-538.
19	IMOTO K, OKADA M, YAMAWAKI H. Periostin mediates right ventricular failure through induction of inducible nitric oxide synthase expression in right ventricular fibroblasts from monocrotaline-induced pulmonary arterial hypertensive rats[J/OL]. Int. J. Mol. Sci., 2018, 20(1): 62[2023-03-23]. .
20	BRUNS D R, TATMAN P D, KALKUR R S, et al.. The right ventricular fibroblast secretome drives cardiomyocyte dedifferentiation[J/OL]. PLoS ONE, 2019, 14(8): e220573[2023-03-23]. .
21	WANG X, LI F, MA D, et al.. Periostin mediates cigarette smoke extract-induced proliferation and migration in pulmonary arterial smooth muscle cells[J]. Biomed. Pharmacother., 2016, 83: 514-520.
22	NIE X, SHEN C, TAN J, et al.. Periostin: a potential therapeutic target for pulmonary hypertension?[J]. Circ. Res., 2020, 127(9): 1138-1152.
23	FRANTZ S, HUNDERTMARK M J, SCHULZ-MENGER J, et al.. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies[J]. Eur. Heart J., 2022, 43(27): 2549-2561.
24	LI L, ZHAO Q, KONG W. Extracellular matrix remodeling and cardiac fibrosis[J]. Matrix Biol., 2018, 68-69: 490-506.
25	KAUR H, TAKEFUJI M, NGAI C Y, et al.. Targeted ablation of periostin-expressing activated fibroblasts prevents adverse cardiac remodeling in mice[J]. Circ. Res., 2016, 118(12): 1906-1917.
26	DIXON I, LANDRY N M, RATTAN S G. Periostin reexpression in heart disease contributes to cardiac interstitial remodeling by supporting the cardiac myofibroblast phenotype[J]. Adv. Exp. Med. Biol., 2019, 1132: 35-41.
27	LIAO Y, LI G, ZHANG X, et al.. Cardiac nestin(+) mesenchymal stromal cells enhance healing of ischemic heart through periostin-mediated M2 macrophage polarization[J]. Mol. Ther., 2020, 28(3): 855-873.
28	XUE K, CHEN S, CHAI J, et al.. Upregulation of periostin through creb participates in myocardial infarction-induced myocardial fibrosis[J]. J. Cardiovasc. Pharmacol., 2022, 79(5): 687-697.
29	BRUNTON-O'SULLIVAN M M, HOLLEY A S, BIRD G K, et al.. Examining variation and temporal dynamics of extracellular matrix biomarkers following acute myocardial infarction[J]. Biomark. Med., 2022, 16(3): 147-161.
30	O'DONNELL A, YUTZEY K E. Mechanisms of heart valve development and disease[J/OL]. Development, 2020, 147(13): dev183020[2023-03-29]. .
31	DI VITO A, DONATO A, PRESTA I, et al.. Extracellular matrix in calcific aortic valve disease: architecture, dynamic and perspectives[J/OL]. Int. J. Mol. Sci., 2021, 22(2): 913[2023-06-09]. .
32	CHEEK J D, WIRRIG E E, ALFIERI C M, et al.. Differential activation of valvulogenic, chondrogenic, and osteogenic pathways in mouse models of myxomatous and calcific aortic valve disease[J]. J. Mol. Cell. Cardiol., 2012, 52(3): 689-700.
33	HAKUNO D, KIMURA N, YOSHIOKA M, et al.. Periostin advances atherosclerotic and rheumatic cardiac valve degeneration by inducing angiogenesis and MMP production in humans and rodents[J]. J. Clin. Invest., 2010, 120(7): 2292-2306.
34	BAMAN J R, PASSMAN R S. Atrial fibrillation[J/OL]. J. Am. Med. Assoc., 2021, 325(21): 2218[2023-04-01]. .
35	SOHNS C, MARROUCHE N F. Atrial fibrillation and cardiac fibrosis[J]. Eur. Heart J., 2020, 41(10): 1123-1131.
36	ROH S, KIM J Y, CHA H K, et al.. Molecular signatures of sinus node dysfunction induce structural remodeling in the right atrial tissue[J]. Mol. Cells, 2020, 43(4): 408-418.
37	FANG L, JIN H, LI M, et al.. Serum periostin as a predictor of early recurrence of atrial fibrillation after catheter ablation[J]. Heart. Vessels., 2022, 37(12): 2059-2066.

[1]	Hao LIU, Xiang LI. Research Progress on Pathogenic Mechanisms and Treatment Strategy of Coronary Artery Disease [J]. Current Biotechnology, 2025, 15(2): 254-262.
[2]	Yeerkenbieke BUERLAN, Lili SUN, Yuemaierabola ANWAIER, Wenjia GUO. Comprehensive Analysis of POSTN in ER⁺ Breast Cancer——Based on Single-cell RNA and Bulk RNA-seq Sequencing [J]. Current Biotechnology, 2024, 14(6): 1055-1066.
[3]	Xingpeng DUAN, Jingli LIU, Che WANG, Dejing SHANG. Effects of Macrophage Scavenger Receptors and Toll-like Receptors on Ox-LDL Uptake and Inflammation [J]. Current Biotechnology, 2024, 14(4): 668-675.
[4]	Xuesheng FANG, Mingwei BAO. Progress on Treatment of Pulmonary Hypertension Based on Neurohormonal System [J]. Current Biotechnology, 2023, 13(6): 889-894.
[5]	Yanyi LI, Na LYU, Jinli CHEN, Xiao LI, Weiting ZHANG, Hongxia ZHANG. Progress on the Mechanism of Soybean Protein Derived Peptides Regulating Glucose and Lipid Metabolism [J]. Current Biotechnology, 2022, 12(6): 853-860.
[6]	Pei ZHAO, Qing ZOU, Zelin LI. Effects of Astragaloside Ⅳ on Ventricular Remodeling and NOX/ROS/TNF-α Signaling Pathways in Rats with Acute Myocardial Infarction [J]. Current Biotechnology, 2022, 12(5): 778-785.
[7]	OUYANG Man. Mechanism Progress on Fibroblast Growth Factor 21 Analogue Treating Atherosclerosis [J]. Curr. Biotech., 2020, 10(5): 463-469.
[8]	LU Tengfei, PEI Wenhua, WU Yangnan, MA Yuehui, GUAN Weijun. Current Status of Vascular Stem/progenitor Cells [J]. Curr. Biotech., 2017, 7(3): 182-186.

Research Advances of POSTN in Cardiovascular Diseases

骨膜蛋白在心血管疾病中的研究进展

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References 37

Related Articles 8

Recommended Articles

Metrics

Comments